Olcegepant
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C38H47Br2N9O5 |
Molar mass | 869.660 g·mol−1 |
3D model (JSmol) | |
| |
|
Olcegepant (INN,[1] code name BIBN-4096BS) is a calcitonin gene-related peptide receptor antagonist being studied as a potential treatment for migraines.[2]
A 2013 meta-analysis found olcegepant and telcagepant were effective and safe compared to placebo.[3]
See also
[edit]References
[edit]- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 48" (PDF). World Health Organization. pp. 256–7. Retrieved 20 March 2017.
- ^ Tfelt-Hansen P, Olesen J (April 2011). "Possible site of action of CGRP antagonists in migraine". Cephalalgia. 31 (6): 748–50. doi:10.1177/0333102411398403. PMID 21383046. S2CID 22049557.
- ^ Yao G, Yu T, Han X, Mao X, Li B (April 2013). "Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis". Neural Regeneration Research. 8 (10): 938–47. doi:10.3969/j.issn.1673-5374.2013.10.009. PMC 4145922. PMID 25206386.